Kesios raises £19m series-A from Abingworth et al.

Kesios is an early-stage developer of new therapies for the treatment of multiple myeloma and other cancers. The company is developing drug candidates that exploit a novel target within the nuclear factor kappa B pathway. According to Kesios, the target appears to be critical in promoting cancer-cell survival in certain white blood cells of patients with multiple myeloma and other malignancies.

The company's lead drug candidate KES-0001 is soon to enter clinical studies as a potential treatment for myeloma.

Kesios was set up in July 2012 to commercialise research led by Professor Guido Franzoso from the Department of Medicine at Imperial College London. The business employs 10 people, based in London.

The fresh funding will be used to support the development of Kesios's new treatments.

People
As part of the deal, Kate Binghan of SV Life Sciences and Kurt von Emster of Abingworth have joined the Kesios board. Maina Bhaman is director of healthcare ventures at Imperial Innovations. Paolo Paoletti is CEO of Kesios.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• UK / Ireland
• Healthcare
• Abingworth Management
• Venture